SPERO THERAPEUTICS, INC. (SPRO)
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
📉 **NEGATIVE** • Low confidence analysis (49%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (21%) **Content type:** Clinical